Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers

Androgen receptor (AR) expression is an emerging prognostic marker that has been observed in 25% to 75% of triple negative breast cancers (TNBCs) that lack estrogen receptor, progesterone receptor and HER2 overexpression. TNBCs are treated with AR-targeted therapies and standardized evaluation of AR expression may help guide patient management. Basal-like TNBCs are a subgroup of TNBCs defined by positive immunoreactivity for CK5/6 or EGFR that carry a worse prognosis. However, it's unclear whether basal-like TNBCs have a different rate of AR positivity or if AR expression is predictive of disease free survival in this patient group.

https://ift.tt/2l77CBD